Comprehensive Review Highlights Tirzepatide's Potential in Treating MASH Liver Disease

Metabolically Dysfunctional-Associated Steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a progressive and severe form of fatty liver disease characterized by inflammation, liver cell damage, and fibrosis, often leading to cirrhosis and liver failure. It is a significant global health burden with increasing prevalence, particularly among individuals with type 2 diabetes and obesity. Despite its severity, there are currently no FDA-approved pharmacological treatments specifically for MASH, highlighting a critical unmet medical need. This review aimed to systematically evaluate the existing evidence on Tirzepatide's efficacy and safety in managing MASH.

The comprehensive review revealed that Tirzepatide, a dual GLP-1 and GIP receptor agonist, consistently demonstrated significant improvements across multiple MASH-related endpoints. In clinical trials, patients receiving Tirzepatide (e.g., 10 mg or 15 mg once weekly) showed a mean reduction of 43% in liver fat content compared to placebo, as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF). Histological improvements were notable, with 2.5-fold higher rates of MASH resolution without worsening of fibrosis in Tirzepatide groups (p<0.001) compared to control. Liver enzyme levels also significantly decreased, with ALT and AST showing reductions of 35% and 30%, respectively, from baseline (p<0.01). > The most compelling finding was that Tirzepatide treatment led to a statistically significant 52% improvement in overall MASH histological scores, including inflammation and ballooning, in 68% of treated patients compared to only 21% in the placebo group (p<0.0001). Furthermore, Tirzepatide consistently improved metabolic comorbidities, resulting in an average body weight loss of 15% and a HbA1c reduction of 1.8% in patients with concurrent type 2 diabetes, indirectly contributing to liver health.